ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
- DOI
- 10.1371/journal.pgen.1010563
- Published
- 2023-01-03
- Container
- PLoS Genet
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1371/journal.pgen.1010563,
title = {ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).},
author = {Ferrando L and Vingiani A and Garuti A and Vernieri C and Belfiore A and Agnelli L and Dagrada G and Ivanoiu D and Bonizzi G and Munzone E and Lippolis L and Dameri M and Ravera F and Ravera F and Colleoni M and Viale G and Magnani L and Ballestrero A and Zoppoli G and Pruneri G.},
year = {2023},
journal = {PLoS Genet},
doi = {10.1371/journal.pgen.1010563},
url = {https://doi.org/10.1371/journal.pgen.1010563}
}RIS
TY - JOUR TI - ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). AU - Ferrando L AU - Vingiani A AU - Garuti A AU - Vernieri C AU - Belfiore A AU - Agnelli L AU - Dagrada G AU - Ivanoiu D AU - Bonizzi G AU - Munzone E AU - Lippolis L AU - Dameri M AU - Ravera F AU - Ravera F AU - Colleoni M AU - Viale G AU - Magnani L AU - Ballestrero A AU - Zoppoli G AU - Pruneri G. PY - 2023 JO - PLoS Genet DO - 10.1371/journal.pgen.1010563 UR - https://doi.org/10.1371/journal.pgen.1010563 ER -
APA
L, F., A, V., A, G., C, V., A, B., L, A., G, D., D, I., G, B., E, M., L, L., M, D., F, R., F, R., M, C., G, V., L, M., A, B., G, Z., & G., P. (2023). ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).. PLoS Genet. https://doi.org/10.1371/journal.pgen.1010563
Source records
- europe-pmc · retrieved 2026-09-27T03:09:36.710Z
- doaj · retrieved 2026-09-27T03:09:36.720Z